Iron chelation

Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study

(2013) Ali T. Taher et al.   ANNALS OF HEMATOLOGY

Results from a 1-year, open-label, single arm, multi-center trial evaluating the efficacy and safety of oral Deferasirox in patients diagnosed with low and int-1 risk myelodysplastic syndrome (MDS) and transfusion-dependent iron overload

(2012) F. Nolte et al.   ANNALS OF HEMATOLOGY

Combined chelation therapy with deferasirox and deferoxamine in thalassemia

(2012) Ashutosh Lal et al.   BLOOD CELLS MOLECULES AND DISEASES

Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT

(2012) P Armand et al.   BONE MARROW TRANSPLANTATION

Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox

(2012) Shohei Kikuchi et al.   FREE RADICAL BIOLOGY AND MEDICINE

Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with  -thalassemia major

(2012) D. J. Pennell et al.   HAEMATOLOGICA

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

(2012) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Substituent Effects on Desferrithiocin and Desferrithiocin Analogue Iron-Clearing and Toxicity Profiles

(2012) Raymond J. Bergeron et al.   JOURNAL OF MEDICINAL CHEMISTRY

Pancreatic iron and glucose dysregulation in thalassemia major

(2011) Leila J. Noetzli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Pituitary iron and volume predict hypogonadism in transfusional iron overload

(2011) Leila J. Noetzli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up

(2011) M. D. Cappellini et al.   BLOOD

Combining two orally active iron chelators for thalassemia

(2010) Vasilios Berdoukas et al.   ANNALS OF HEMATOLOGY

Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity

(2010) Raymond J. Bergeron et al.   BIOMETALS

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

(2010) J. C. Wood et al.   BLOOD

Controversies surrounding iron chelation therapy for MDS

(2010) Heather A. Leitch   BLOOD REVIEWS

A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload

(2010) H. Y. Rienhoff et al.   HAEMATOLOGICA

Retrospective Study on the Combination of Desferrioxamine and Deferasirox for Treatment of Iron-overloaded Thalassemic Patients: First Evidence of More Than 2 Years

(2010) Arunee Jetsrisuparb et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

(2010) Norbert Gattermann et al.   LEUKEMIA RESEARCH

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

(2010) Roberto Guariglia et al.   LEUKEMIA RESEARCH

Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients

(2010) Esther Natalie Oliva et al.   TRANSFUSION

Severe iron overload in Blackfan-Diamond anemia: A case-control study

(2009) Simona Roggero et al.   AMERICAN JOURNAL OF HEMATOLOGY

Efficacy of deferasirox in reducing and preventing cardiac iron overload in  -thalassemia

(2009) D. J. Pennell et al.   BLOOD

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

(2009) Ali Taher et al.   BRITISH JOURNAL OF HAEMATOLOGY

Elevated pretransplant ferritin is associated with a lower incidence of chronic graft-versus-host disease and inferior survival after myeloablative allogeneic haematopoietic stem cell transplantation

(2009) Anuj Mahindra et al.   BRITISH JOURNAL OF HAEMATOLOGY

Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major

(2009) Kallistheni Farmaki et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cardiac T2* Magnetic Resonance for Prediction of Cardiac Complications in Thalassemia Major

(2009) P. Kirk et al.   CIRCULATION

Safety and Efficacy of Combined Chelation Therapy with Deferasirox and Deferoxamine in a Gerbil Model of Iron Overload

(2008) Maya Otto-Duessel et al.   ACTA HAEMATOLOGICA

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

(2008) E. Messa et al.   ACTA HAEMATOLOGICA

Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts

(2008) Cheng E. Chee et al.   AMERICAN JOURNAL OF HEMATOLOGY

International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: Impact of cytopenias on clinical outcomes in myelodysplastic syndromes

(2008) Jelena M. Kao et al.   AMERICAN JOURNAL OF HEMATOLOGY